For research use only. This reference describes retatrutide strictly as a chemical compound used in cell-based receptor pharmacology and animal research. Research-grade retatrutide is not equivalent to, and is not a substitute for, any FDA-approved pharmaceutical product of a similar name. Nothing here is intended for human or animal consumption. We make no health, performance, or therapeutic claims of any kind. For full context, see our research-use disclaimer.
Retatrutide — development code LY3437943, sometimes referenced under sponsor program names — is a synthetic 39-amino-acid peptide built on a glucose-dependent insulinotropic polypeptide (GIP) backbone. It engages three Class B G-protein-coupled receptors as an agonist: the glucagon-like peptide-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). What follows covers the peptide's primary structure, the three non-coded residues that give it protease resistance and receptor-tuned activity, the cryo-EM evidence for how a single continuous α-helix engages all three receptors, the comparative receptor-level potency profile, the structural class it belongs to, and the current regulatory picture for laboratories ordering material.
Primary structure: a 39-residue GIP-derived peptide
Retatrutide's chemical identity sits in well-defined territory for an actively-investigated peptide. The compound is documented in encyclopedic references and in the structural literature as a synthetic 39-amino-acid sequence built on a GIP backbone. The 2024 Cell Discovery cryo-EM paper by Sun and colleagues resolves its structure bound to each of the three target receptors and is the primary reference for the architectural details that follow.
Why a GIP backbone
The choice of starting backbone is itself informative. Among the three target receptors, the GIP receptor is the most divergent from native GLP-1 in the binding-pocket details that matter for ligand recognition. Designing from a GIP-derived sequence makes triple-receptor engineering more tractable than starting from GLP-1: the harder selectivity problem is closer to solved at the outset, and the easier modifications fall on the GLP-1R and GCGR ends. Several other multi-receptor peptide programs have made the same backbone choice for the same reason.
Lipidation at Lys17
The peptide is acylated at lysine 17 with a C20 fatty diacid moiety connected via a γGlu-2×OEG linker. That fatty diacid enables high-affinity, reversible binding to serum albumin — the structural mechanism behind the long pharmacokinetic half-life shared with other once-weekly peptide agonists in the same structural class. The lipidation strategy is older than retatrutide. It was first demonstrated in earlier-generation peptide drugs and has since become a standard tool for tuning the half-life of large therapeutic peptides without changing their receptor pharmacology.
Engineered modifications: three non-coded residues
Three positions in retatrutide carry non-canonical amino acids — α-aminoisobutyric acid (Aib) at positions 2 and 20, and α-methyl-L-leucine (αMeL) at position 13. Each one earns its place for a specific structural reason.
Aib2 — protease resistance
Native GLP-1 and GIP get cleaved at their N-termini by dipeptidyl peptidase 4 (DPP-4). The enzyme cuts between residues 2 and 3 in both peptides. Aib at position 2 introduces backbone constraints that the DPP-4 active site can't accommodate, and the cryo-EM analysis confirms that Aib2 is the principal structural feature behind the molecule's DPP-4 resistance — the same modification has been used in other Class B GPCR peptides for the same reason.
αMeL13 — GIP-receptor activity
α-methyl-L-leucine at position 13 supports activity at the GIP receptor. α-methyl substitution at chiral centers is a common medicinal-chemistry technique: it locks side-chain orientation against the protein binding surface and reduces conformational entropy on binding. In retatrutide, this is the single residue most credited with maintaining GIPR engagement when the rest of the sequence is tuned for the other two receptors.
Aib20 — pharmacokinetic and developability properties
The second Aib appears at position 20. Reviewers describe its contribution as overall stability and developability — a less specific change, but a useful one that supports the molecule's pharmacokinetic profile. Aib placements like this are typical of late-stage medicinal chemistry, where a small handful of substitutions can shift handling characteristics without disturbing the activity-relevant binding interface.
